http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo#Head http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo#assertion http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo#provenance http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo#pubinfo http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo#assertion http://purl.obolibrary.org/obo/DOID_9008 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_9008 http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01234 http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo#association http://www.w3.org/2000/01/rdf-schema#label allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment atopic dermatitis bronchial asthma contact dermatitis drug hypersensitivity reactions seasonal or perennial allergic rhinitis and serum sickness collagen diseases during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus and acute rheumatic carditis dermatologic diseases bullous dermatitis herpetiformis exfoliative dermatitis mycosis fungoides pemphigus severe erythema multiforme stevens johnson syndrome severe psoriasis and severe seborrheic dermatitis edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia hypercalcemia associated with cancer and nonsuppurative thyroiditis gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis and regional enteritis hematologic disorders idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia and congenital erythroid hypoplastic anemia miscellaneous diagnostic testing of adrenocortical hyperfunction tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy and trichinosis with neurologic or myocardial involvement neoplastic diseases for palliative management of leukemia and lymphomas in adults and acute leukemia of childhood ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis and sympathetic ophthalmia respiratory diseases symptomatic sarcoidosis loeffler s syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy and aspiration pneumonitis rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require low dose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post traumatic osteoarthritis synovitis of osteoarthritis and epicondylitis http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB01234 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo#provenance http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo#pubinfo http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo#sig http://purl.org/nanopub/x/hasSignature ZdCHl0hK2ChfvyjAxVw7wSqUdiI2MfKVIgg/Zt3wDqbZg0nJy5a7fTb51jdQc2+qQoW8vyGqPF/1wejnYAlzEIDVe8mUfw9tow/XsqHI65RBdMy/kxv/eASAUW2PxIqc6SN1GEahVw715lA3Nyr9EPK7VIzLxSJOIDNGZ+ND31U= http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo http://purl.org/dc/terms/created 2021-07-03T12:47:54.342+02:00 http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAyadVIKes2ds9sKTuXYCmHou4HyLz4YPf1Js4zNhfLWo https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs